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SUMMARY – Infl ammation, apoptosis and extracellular remodeling play signifi cant roles in car-
diovascular disease (CVD) underlying the major causes of mortality in renal patients. In 19 pre-dial-
ysis patients, 21 dialysis patients and 20 control subjects, the concentrations of pentraxin-3, galectin-3, 
MMP-9 and TIMP-1 were determined by ELISA. CVD risk was calculated according to the Fram-
ingham risk score algorithm. Pentraxin-3 was increased in renal patients compared to healthy controls 
(p<0.001). In contrast, galectin-3 was reduced in hemodialysis patients compared to pre-dialysis pa-
tients and controls (p<0.001). In addition, MMP-9 and TIMP-1 were elevated in renal patients com-
pared to controls (p<0.01 and p<0.001, respectively). Logistic regression analyses disclosed associa-
tions of galectin-3, MMP-9, pentraxin-3 and glomerular fi ltration with calculated CVD risk score. 
Combined testing of pentraxin-3, galectin-3, MMP-9 and glomerular fi ltration rate can discriminate 
renal patients with high and low risk of a coronary event.
Key words: Kidney diseases; Pentraxin-3; Galectin-3; Matrix-metalloproteinase-9; Tissue inhibitor of 
matrix metalloproteinase-1; Risk factors; Risk assessment; Cardiovascular diseases
Correspondence to: Milica Miljković, MD, MS, Department of 
Medical Biochemistry, Faculty of Pharmacy, Vojvode Stepe 450, P. 
Box 146, 11000 Belgrade, Serbia
E-mail: milicammiljkovic@gmail.com
Received September 5, 2016, accepted May 29, 2017
Introduction
Chronic kidney disease (CKD) represents a sig-
nifi cant health problem worldwide. Th e increasing 
prevalence of hypertension and diabetes as the main 
factors will further enhance the number of patients de-
veloping end-stage renal disease (ESRD)1.
Cardiovascular disease (CVD), chronic low-grade 
infl ammation and protein-energy wasting are present 
in a large proportion of patients with advanced CKD2, 
and each of these factors independently predicts their 
outcome2,3.
Pentraxin-3, an acute-phase protein, plays an im-
portant role in the regulation of infl ammatory reac-
tions, clearance of apoptotic cells and resistance to 
pathogens2. Tong et al.2 showed that pentraxin-3 has a 
predictive value for mortality in CKD.
Progressive renal disease is a consequence of dis-
equilibrium between the increased synthesis of extra-
cellular matrix components and their decreased degra-
dation, which occurs as a result of imbalanced matrix 
metalloproteinase (MMP) activities and their tissue 
inhibitors (TIMP), leading to nephron loss4. Increased 
infl ammation and oxidative stress enhance MMP ex-
pression and activity, thus increasing the prevalence of 
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numerous diseases including atherosclerosis, nephritis 
and fi brosis5. MMP-9 is a zinc-dependent enzyme in-
volved in tissue remodeling which includes degrada-
tion of extracellular matrix components, as well as the 
processing of non-matrix substrates4. In contrast, 
TIMP-1 is a specifi c endogenous inhibitor that binds 
MMP-9 and suppresses its activity5.
Galectin-3, a molecule with diverse biological ac-
tivities, might play a role within the complex maze of 
connections that link infl ammation, extracellular ma-
trix remodeling and apoptosis. Th e former is a multi-
functional lectin with a broad range of actions includ-
ing anti-adhesion, binding advanced glycation end-
products (AGE), regulation of gene expression and 
controlling cell proliferation and death6. However, 
more recent evidence suggests that galectin-3 is an 
anti-apoptotic and anti-fi brotic agent, thus function-
ing to prevent further CKD development7. Due to its 
diversity of actions, the role of galectin-3 in progres-
sive renal disease remains controversial.
From 1948, the Framingham study strived to iden-
tify common factors contributing to CVD over a long 
period of time. Hypertension, smoking, hyperlipid-
emia and age were found to be independent risk fac-
tors for CVD. Th e study employed the Framingham 
risk score (FRS) algorithm in order to predict an acute 
coronary event within the next 10 years8.
Our present study aimed to assess circulating pen-
traxin-3, galectin-3, MMP-9 and TIMP-1 concentra-
tions in diff erent stages of CKD, in both dialysis and 
non-dialysis patients, as well as in a control group. We 
also assessed association between plasma concentra-
tions of pentraxin-3, galectin-3, MMP-9, TIMP-1 
and estimated glomerular fi ltration rate (eGFR) with 
the FRS. Using pentraxin-3, galectin-3 and MMP-9/
TIMP-1 as markers which are in various ways in-
volved in the pathology of renal disease and eGFR as 
a common indicator of kidney function, we tried to 
fi nd out whether there is diff erence in the FRS be-
tween diff erent stages of kidney failure.
Material and Methods
Subjects
Th is study included 40 renal disease patients from 
the Department of Nephrology, Clinical Centre of 
Serbia, Belgrade. Nineteen of them were pre-dialysis 
patients with CKD stage 2-4, not requiring hemodi-
alysis (10 men and 9 women, mean age 53.5±18.54 
years), while the remaining 21 patients (15 men and 6 
women, mean age 53.8±14.41 years) were ESRD pa-
tients receiving dialysis [average duration 52.3 (26.8-
102.4) months]. Th e original kidney diseases in CKD 
and ESRD patients were: chronic glomerulonephritis 
(n=6), nephroangiosclerosis (n=3), diabetic nephropa-
thy (n=9), polycystic kidney disease (n=3), other (n=14) 
and unknown diagnosis (n=5). ESRD patients on 
thrice-weekly maintenance hemodialysis treatment 
(each time 4-5 hours) received a bicarbonate-based so-
lution using polyamide and polysulfone low-fl ux or 
high-fl ux membranes. CKD patients with some form 
of glomerulonephritis as the main disease received 
corticosteroids or other immunosuppressive therapy 
according to general protocols. Th e control group con-
sisted of 20 healthy subjects free of infl ammation, neu-
rological dysfunction, history of CVD, renal, gastroin-
testinal, pulmonary, hepatic and oncologic disease not 
taking any prescribed medication.
Th e study was planned according to the ethical 
guidelines detailed in the Declaration of Helsinki. Th e 
Ethics Committee of the Clinical Center of Serbia 
and the Ethics Committee of the Faculty of Pharmacy, 
University of Belgrade evaluated and approved the 
study protocol. Informed consent was voluntarily ob-
tained from all study participants.
Sample collection
Blood samples were collected after a 12-h fasting 
period. Serum was separated by centrifugation at 
1500xg for 10 min, aliquoted and stored at -80 °C for 
up to one month until analysis. Blood was collected 
from patients immediately prior to dialysis.
Biochemical analyses
Total cholesterol and triglycerides were measured 
by standard automated enzymatic methods (Biosys-
tems S.A., Barcelona, Spain) using ILab 300+ (Instru-
mentation Laboratory, Milan, Italy). Plasma HDL-C 
was determined using a direct assay (Biosystems S.A., 
Barcelona, Spain), whereas LDL-C cholesterol con-
centration was calculated using the Friedewald for-
mula. Serum urea, creatinine, uric acid, total proteins 
and glucose were measured by routine laboratory 
methods (Bio Systems S.A., Barcelona, Spain) with an 
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ILab 300+ analyzer. Th e eGFR was calculated using 
the Modifi cation of Diet in Renal Disease equation 
(MDRD)9.
ELISA
Serum concentrations of pentraxin-3, galectin-3, 
MMP-9 and TIMP-1 were determined by ELISA 
(R&D systems, Minneapolis, USA).
Framingham risk score calculation
Th e risk of CVD was calculated according to the 
FRS algorithm. Calculation of FRS was based on age, 
gender, smoking, blood pressure, total and HDL cho-
lesterol as coronary risk factors. According to this 
score, all study participants were divided into three 
categories indicating low (<10%), medium (10%-20%) 
and high (>20%) risk of an acute coronary event with-
in the next 10 years8.
Statistical analyses
Data are shown as mean ± standard deviation (SD) 
for normally distributed variables, or as geometric 
mean with 95% confi dence interval (95% CI) or as 
median and interquartile range for parameters not 
normally distributed. Diff erences among continuous 
variables were assessed using ANOVA or Kruskal-Wal-
lis test, where appropriate. Analyses of categorical vari-
ables used the χ2-test for contingency tables. A value of 
p<0.05 was considered statistically signifi cant. In renal 
patients, the possible independent association between 
CVD risk and concentrations of galectin-3, pentrax-
in-3, MMP-9, TIMP-1 and eGFR was tested by bi-
nary logistic regression. Th e low-risk category was 
used as the reference group and was coded 0, while the 
high-risk group was coded 1. Th ree models were test-
ed, as follows: Model 1 – pentraxin-3, galectin-3, 
MMP-9; Model 2 – pentraxin-3, galectin-3, glomeru-
lar fi ltration; and Model 3 – pentraxin-3, galectin-3, 
MMP-9, glomerular fi ltration. We constructed receiv-
er operating characteristic (ROC) curves with the pre-
dictive probabilities from diff erent logistic regression 
models and performed pair-wise comparisons using 
the areas under the ROC curve (AUCs). According to 
the Hosmer and Lemeshow10 rules for the logistic 
models, the discriminative abilities of the models were 
classifi ed per their AUC values as poor: (0.5≤AUC<0.7), 
acceptable (0.7≤AUC<0.8), excellent (0.8≤AUC<0.9) 
or outstanding (AUC ≥0.9)10
For all analyses, the SPSS software (IBM®SPSS®
version 22.0) was used.
Results
Table 1 contains data on the subjects involved in 
this study and the results of biochemical analyses 
within the study groups (CKD-pre-dialysis patients, 
ESRD-dialysis patients and healthy controls). De-
creased HDL-C (p<0.01) was evident in renal patients 
in comparison with healthy subjects. HDL-C was also 
signifi cantly lower in patients on dialysis (p<0.01). As 
expected, dialysis patients showed increased creatinine 
compared to pre-dialysis patients and controls. Serum 
concentrations of urea, creatinine and uric acid were 
signifi cantly higher in dialysis patients compared with 
pre-dialysis patients and controls. Diff erences in se-
rum concentrations of total and LDL-C, triglycerides 
and fasting glucose between the groups were not sta-
tistically signifi cant (p>0.05). As expected, after taking 
into account all the results and analyzing the FRS al-
gorithm, we found that renal disease patients had an 
increased risk of CVD development as compared to 
the control group, but there was no diff erence between 
the subgroups of renal patients.
Diff erences between pre-dialysis patients, dialysis 
patients and controls in the concentrations of pentrax-
in-3, galectin-3, MMP-9 and TIMP-1 are shown in 
Table 2. Pentraxin-3 was signifi cantly increased in 
both groups of renal patients compared to controls 
(p<0.001). In contrast, galectin-3 was reduced in dialy-
sis patients compared to the pre-dialysis and control 
groups (p<0.001). In addition, MMP-9 and TIMP-1 
were elevated in renal patients compared to controls 
(p<0.01 and p<0.001, respectively).
In the present study, we investigated diff erent mod-
els in order to discriminate renal patients with high 
and low risk of CVD according to FRS values. To ac-
complish this, we constructed ROC curves with pre-
dictive probabilities and calculated AUCs (Table 3). 
Only combinations between parameters with signifi -
cant AUC values are reported. According to the Hos-
mer and Lemeshow rule, the AUC (0.732) for Model 
2, which included pentraxin-3, galectin-3, MMP-9 
and glomerular fi ltration, was acceptable. However, a 
pair-wise comparison of ROC curves showed that this 
improvement was not statistically signifi cant (p=0.453).
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Table 1. Demographic characteristics and standard biochemical parameters in pre-dialysis, dialysis patients 
and control group
Variable Control group Pre-dialysis patients Hemodialysis patients p value
Age (yrs) 46.7±10.01 53.5±18.54 52.6±13.74 0.282
Gender, male/female 12/8 10/9 15/6 0.466
FRS,% 3.4 (2.0-5.7) 21.2 (15.7-28.8) 20.1 (15.7-25.9) <0.001b,c
eGFR, mL/min/1,73m2 90±10.1 17.4±11.08 6.2±2.33 <0.001a,b,c
Glucose, mmol/L 5.1 (4.820-5.46) 5.4 (4.80-7.32) 5.3 (4.72-6.15) 0.189
Total cholesterol, mmol/L 4.9±0.99 5.2±1.34 4.5±1.42 0.198
HDL-C, mmol/L 1.6 (1.43-1.90) 0.9 (0.92-1.07) 0.8 (0.66-0.93) < 0.01a,b,c
LDL-C, mmol/L 2.9 (2.53-3.03) 3.1 (2.56-3.78) 2.6 (2.14-3.13) 0.314
Triglycerides, mmol/L 1.1 (0.88-1.38) 1.5 (1.21-1.97) 1.6 (1.22-2.09) 0.097
Uric acid, μmol/L 345±85.4 546±125.8 422±103.1 < 0.01a,b
Creatinine, μmol/L 84.1 (78.8-89.8) 363 (281.7-467.7) 824 (699.9-972.3) < 0.01a,b,c
Urea, mmol/L 5.6 (5.04-6.96) 21.7 (18.92-24.55) 22.5 (19.11-24.30) <0.01b,c
Data are expressed as mean ± standard deviation; creatinine, triglycerides, HDL-C and LDL-C are presented as geometric mean and 95% 
confi dence interval (95% CI) derived from log-normal values; urea and glucose are shown as median and interquartile range; continuous 
variables were compared using ANOVA or Kruskal-Wallis test; Tukey’s post hoc test was used for subgroup diff erences; categorical vari-
ables (gender) were compared using the χ2-test; FRS = Framingham risk score; LDL-C = low density cholesterol; HDL-C = high density 
cholesterol; eGFR = glomerular fi ltration rate; p = statistical diff erences between control subjects and renal patients; astatistically signifi cant 
diff erences between pre-dialysis and dialysis patients; bstatistically signifi cant diff erences between pre-dialysis patients and control group; 
cstatistically signifi cant diff erences between dialysis patients and control group
Table 2. Concentrations of pentraxin-3, galectin-3, matrix metalloproteinase-9 (MMP-9) and tissue inhibitor 
of matrix metalloproteinase-1 (TIMP-1)
Variable Control group Pre-dialysis patients Hemodialysis patients p value
Pentraxin-3 (ng/mL) 0.39 (0.218-0.727) 1.31 (0.880-1.961) 1.77 (1.144-2.745) <0.001b,c
Galectin-3 (ng/mL) 2.4 (2.058-3.986) 2.24 (1.674-2.894) 0.82 (0.512-1.602) <0.001a,c
MMP-9 (ng/mL) 141 (94-211) 376 (275-515) 304 (236-392) <0.01c
TIMP-1 (ng/mL) 138 (115-166) 515 (398-665) 484 (416-563) <0.001b,c
Concentrations of pentraxin-3, MMP-9 and TIMP-1 are presented as geometric mean and 95% confi dence interval derived from log-
normal values; galectin-3 concentration is median and interquartile range; continuous variables were compared using ANOVA or Kruskal-
Wallis test; categorical variables (gender) were compared using the χ2 test; p = statistical diff erences between control subjects and renal 
patients; astatistically signifi cant diff erences between pre-dialysis and dialysis patients; bstatistically signifi cant diff erences between pre-di-
alysis patients and control group; cstatistically signifi cant diff erences between dialysis patients and control group
Table 3. Results of ROC curve analysis for discriminating 
subjects with high cardiovascular disease (CVD) risk 
from subjects with low CVD risk
AUC Confi dence interval
Standard 
error p
a
Model 1 0.700b 0.505-0.855 0.102
Model 2 0.732b 0.536-0.878 0.094
Model 3 0.716b 0.519-0.867 0.096 0.453
Model 1 = pentraxin-3, galectin-3 and MMP-9; Model 2 = pen-
traxin-3, galectin-3 and glomerular fi ltration; Model 3 = pentrax-
in-3, galectin-3, MMP-9 and glomerular fi ltration; ap values for 
testing diff erences in AUCs between Model 1, Model 2 and Model 
3; bAUC signifi cantly diff erent from 0.5
Discussion
Infl ammation in CKD is one of the most impor-
tant factors involved in initiating and progression of 
atherosclerosis, which is the main cause of morbidity 
and mortality in these patients. Increased infl amma-
tion in renal pathology may be explained by the pres-
ence of other illnesses, elevated oxidative stress, bio-
incompatible dialyzers, urinary tract infections, and 
increased production/decreased clearance of infl am-
matory cytokines11.
Pentraxin-3 (PTX3), an acute phase protein, is 
produced by a variety of tissues and cells, as well as in 
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the human renal cortex, medulla, glomeruli, and in the 
mesangial cells after stimulation with interleukin-1 
(IL-1) and tumor necrosis factor-α (TNF-α)12. In our 
study, we showed that both patient groups had higher 
PTX3 than controls, with the highest concentration 
tending to be in dialysis patients (Table 2). Increased 
PTX3 levels could be explained as a consequence of 
impaired kidney function and its enhanced synthesis 
and release in peripheral tissues13. Given that multiple 
studies have reported a negative correlation between 
PTX3 concentration and glomerular fi ltration in 
CKD2,14, increased PTX3 could also be explained by 
its decreased clearance. PTX3 is a prototype of long 
pentraxins; a large molecule with molecular weight of 
40.6kD characterized by a pentameric structure, which 
can result in increased retention during uremia15. A re-
cent fi nding also suggests that PTX3 can induce mor-
phological changes in mesangial cells, causing contrac-
tion and consequential reduction in the glomerular 
fi ltration area16. Furthermore, considering that these 
patients are permanently in a low-grade infl ammatory 
state, PTX3 could be involved in the innate immune 
response against pathogens, regulation of infl amma-
tory reactions, as well as in the removal of apoptotic 
cells11. In addition, our present study found markedly 
higher PTX3 concentration in patients undergoing 
dialysis (Table 2). A pathological uremic milieu can 
cause enhanced release of IL-1β and TNF-α which 
induce production of PTX3 leading to continuous sys-
temic low-grade infl ammation17. In agreement with 
our fi ndings is a study by Rusnati et al., which sug-
gested that PTX3 expression was probably related to 
the processes of matrix deposition, angiogenesis and 
tissue repair18.
Mounting evidence indicates that besides dyslipid-
emia, infl ammation and oxidative stress, extensive vas-
cular remodeling contributes to the initiation and/or 
progression of CKD19. Matrix metalloproteinases and 
their TIMPs play an important role in maintaining the 
equilibrium between the formation and degradation of 
extracellular matrix (ECM) proteins4. Considering 
that the main eff ect of MMPs is degradation, it is well 
documented that in the early stages of kidney disease 
MMPs contribute to the breakdown of collagen type 
IV, the primary component of the ECM in glomerular 
basal membranes and mesangial matrix20. Our results 
indicated that pre-dialysis and dialysis patients had el-
evated concentrations of MMP-9 and TIMP-1 in 
comparison with controls (Table 2), probably indicat-
ing that increased production of MMP-9 would result 
in excessive degradation of the ECM21. In contrast, 
incorrect timing for MMP inhibition during disease 
has been described with increased TIMP inhibition 
and subsequent decreased MMP activity, resulting in 
deposition of ECM in CKD and renal fi brosis22,23. In-
creased levels of TIMP-1 were present in the patients 
suggesting that prolonged increased inhibition of 
MMP-9 could have been a factor for the development 
of fi brosis at a later period23. Previous fi ndings sug-
gested that oxidative stress and infl ammation could be 
additional factors that induce MMP-9 expression and 
synthesis18,24. As MMP-9 is released by neutrophils, 
monocytes and macrophages during the course of an 
infl ammatory response, increased infl ammation found 
in these patients could be a possible reason for elevated 
levels of MMP-9 and consequently TIMP-1 in dialy-
sis and non-dialysis groups compared with controls. 
Further evidence also indicates that this imbalance be-
tween MMP-9 activity and appropriate TIMP-1 inhi-
bition is associated with atherosclerotic development 
in CKD, as well as with disease progression22.
Galectin-3 is a multifunctional β-galactoside-
binding lectin responsible for many physiological and 
pathophysiological processes in the human body. It is 
involved in organogenesis, in the production of proin-
fl ammatory cytokines, the induction of oxidative stress, 
Fig. 1. Comparison of ROC curves: 
Model 1 – pentraxin-3, galectin-3 and MMP-9; 
Model 2 – pentraxin-3, galectin-3 and glomerular 
fi ltration; and Model 3 – pentraxin-3, galectin-3, 
MMP-9 and glomerular fi ltration.
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in alternative macrophage activation and in apoptosis6. 
However, recent evidence suggests protective eff ects of 
galectin-3. It enhances matrix remodeling, protection 
from fi brosis, and it is a receptor for AGE25. AGEs are 
glycated proteins or lipids present in many diff erent 
cell types and implicated in both micro- and macro-
vascular complications of diabetes, which are the main 
causes of CKD26. Galectin-3 has been recently identi-
fi ed as an AGE receptor with high affi  nity for binding, 
internalization and degradation of AGE25. In contrast 
to Receptor for Advanced Glycation End products 
(RAGE) receptors, which promote tissue damage 
through the induction of oxidative stress, galectin-3 
removes AGE and prevents renal injury27. In the pres-
ent study, we showed that dialysis patients had de-
creased galectin-3 compared to pre-dialysis patients 
and controls, implicating reduced AGE removal from 
tissue and circulation. In addition, it has been demon-
strated that AGEs promote ECM deposition via reg-
ulation of various cytokines26. We assume that de-
creased galectin-3 results in elevated AGE levels and 
enhanced uptake by RAGE receptors, subsequently 
followed by increased oxidative stress and ECM depo-
sition.
As mentioned above, ECM remodeling is a critical 
process in renal pathology. Besides MMP and TIMP 
equilibrium, which is important for balancing synthe-
sis, deposition and degradation, it has been suggested 
that galectin-3 may represent a second major pathway 
impacting on ECM remodeling1. Cuttle et al. demon-
strated that tissue architecture of the interstitial matrix 
in galectin-3-defi cient mice was more disorganized 
compared to wild type mice28. Th is fi nding implies that 
the anti-fi brotic eff ects of galectin-3 might be a conse-
quence of enhanced ECM turnover. Our data demon-
strate decreased galectin-3 in dialysis patients com-
pared to pre-dialysis patients and controls, presumably 
indicating poor regulation of ECM organization in 
dialysis patients. In an animal fi brosis model, the se-
verity was signifi cantly increased in galectin-3-defi -
cient mice compared to wild type counterparts after 
unilateral ureteral obstruction29. Th is indicates the po-
tential protective role of galectin-3 in attenuation of 
fi brosis severity during advanced stages of chronic kid-
ney injury. Intracellular galectin-3 is a well-known 
anti-apoptotic factor, primarily localized in the cyto-
plasm where it inhibits activation of caspases, in a 
similar way as Bcl-2. It has also been shown that galec-
tin-3 enhances recovery of tubular cells through limi-
tation of apoptosis and promotion of cell proliferation 
during chronic kidney injury. Taking into consider-
ation all these facts, decreased galectin-3 concentra-
tion in dialysis patients might indicate increased apop-
totic processes, which lead to more profound chronic 
renal failure29.
Th e analysis of ROC curves and AUCs revealed 
the combination of galectin-3, pentraxin-3, MMP-9 
with glomerular fi ltration rate to be the best discrimi-
nator between patients with low and high risk of CVD 
development. As expected, FRS confi rmed previous 
fi ndings that renal patients had an increased risk of a 
coronary event compared with healthy subjects. We 
also found that in addition to glomerular fi ltration, ga-
lectin-3, pentraxin-3 and MMP-9 could be potent 
predictors of high CVD risk in renal patients. Consid-
ering these fi ndings, we assume that diff erentiation of 
renal patients with low and high CVD risk could be 
the potential clinical signifi cance of this research. Th e 
relatively small number of renal patients in our study 
may represent a limitation. Further studies with larger 
sample sizes are needed to re-evaluate our current ob-
servations.
Conclusion
Our results provide a robust link between infl am-
mation, ECM organization and apoptosis, which 
forms the basis for future in-depth studies. Long-term 
low-grade infl ammation represented with increased 
pentraxin-3 can induce an imbalance between MMP-
9 and TIMP-1 leading to fi brosis in end-stage renal 
patients. Th is misbalance can be potentiated by de-
creased galectin-3 in dialysis patients. Our results also 
confi rmed the diverse roles of galectin-3, which be-
sides its proinfl ammatory role also protects renal tu-
bules from chronic injury by limiting apoptosis and 
fi brosis. All the above-mentioned interactions contrib-
ute to the increased risk of CVD, which is the leading 
mortality cause in renal disease patients.
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Sažetak
UDRUŽENOST PENTRAKSINA-3, GALEKTINA-3 I MMP-9/TIMP-1 
S KARDIOVASKULARNIM RIZIKOM U BOLESNIKA S BUBREŽNOM BOLEŠĆU
M. Miljković, A. Stefanović, N. Bogavac-Stanojević, S. Simić-Ogrizović, J. Dumić, D. Černe, 
Z. Jelić-Ivanović i J. Kotur-Stevuljević
Upala, apoptoza i remodeliranje ekstracelularnog matriksa igraju značajnu ulogu u razvoju kardiovaskularnih bolesti 
(KVB) koje su glavni uzrok smrtnosti kod bubrežnih bolesnika. Kod 19 prijedijaliznih i 21 dijaliznog bolesnika, kao i kod 20 
zdravih kontrolnih osoba koncentracije pentraksina-3, galektina-3, MMP-9 i TIMP-1 određene su pomoću tehnike ELISA. 
Rizik od KVB izračunat je prema Framinghamskom algoritamu. Pentraksin-3 je bio povećan kod bubrežnih bolesnika u 
usporedbi sa zdravim kontrolama (p<0,001). Nasuprot tome, galektin-3 je bio smanjen kod bolesnika na hemodijalizi u 
 odnosu na predijalizne bolesnike i kontrole (p<0,001). Uz to, vrijednosti MMP-9 i TIMP-1 su bile povišene kod bubrežnih 
bolesnika u usporedbi s kontrolama (p<0,01 i p<0,001). Logističke regresijske analize pokazale su povezanost udruženih 
galektina-3, MMP-9, pentraksina-3 i glomerularne fi ltracije s izračunatim rezultatom rizika od KVB. Kombinirana ispiti-
vanja pentraksina-3, galektina-3, MMP-9 i glomerularne fi ltracije mogla bi razlikovati bubrežne bolesnike s visokim i niskim 
rizikom od koronarnog događaja.
Ključne riječi: Bubrežne bolesti; Pentraksin 3; Galektin 3; Matriksna metaloproteinaza 9; Tkivni inhibitor matriksne metalo-
proteinaze 1; Rizični čimbenici; Rizik, procjena; Kardiovaskularne bolesti
